Ascentage Pharma Group International
Forward trial catalysts linked to AAPG
CSA tracks 3 forward catalysts for Ascentage Pharma Group International across 2 assets, spanning Phase 3. The nearest is a readout expected Mar 31, 2027 (day precision). Confidence across its tracked catalysts breaks down as 3 medium. Tracked indications include CLL/SLL, Acute Myeloid Leukemia, Ph+ ALL, and 2 more.
AAPG in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Ascentage Pharma Group International has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
5 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| olverembatinib | NCT06640361 catalyst | Phase 3 | Recruiting | 2027-03-31 | Experimental | Ascentage Pharma Group Inc. | GIST |
| olverembatinib | NCT06423911 | Phase 3 | Recruiting | 2027-06-30 | Other | Ascentage Pharma Group Inc. | Chronic Myeloid Leukemia; CML; CML, Chronic Phase |
| lisaftoclax | NCT06319456 catalyst | Phase 3 | Recruiting | 2027-08 | Experimental | Ascentage Pharma Group Inc. | CLL/SLL |
| olverembatinib | NCT06051409 catalyst | Phase 3 | Recruiting | 2027-12-31 | Experimental | Ascentage Pharma Group Inc. | Ph+ ALL; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive |
| lisaftoclax | NCT06389292 | Phase 3 | Recruiting | 2028-05-25 | Experimental | Ascentage Pharma Group Inc. | Acute Myeloid Leukemia |
Every trial the CSA sample links to AAPG's tracked assets, including trials where the asset is not the experimental arm.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →